
Atossa Genetics (ATOS) Stock Forecast & Price Target
Atossa Genetics (ATOS) Analyst Ratings
Bulls say
Atossa Therapeutics Inc is positioned favorably due to its focus on developing proprietary medicines targeting areas of high unmet medical need, notably in oncology and COVID-19. The company's ongoing development of Endoxifen for breast cancer, coupled with its promising COVID-19 therapies, AT-H201 and AT-301, highlights its commitment to innovative therapeutics, which could serve as significant growth drivers. Current analyses indicate an attractive valuation, suggesting potential upside, particularly as the company approaches key clinical milestone achievements that are expected to act as catalysts for stock performance.
Bears say
Atossa Therapeutics Inc reported a net loss of $8.4 million, resulting in an earnings per share (EPS) of $(0.07), which was below both company and consensus estimates of $(0.06). The company faces several significant risks, including balance sheet and liquidity concerns, the potential failure of its product candidates to prove safety and efficacy in clinical trials, and challenges related to regulatory approvals and commercialization. Additionally, external factors such as market competition, changing macroeconomic conditions, and fluctuating investor sentiment toward biotech stocks further contribute to a negative outlook for the company.
This aggregate rating is based on analysts' research of Atossa Genetics and is not a guaranteed prediction by Public.com or investment advice.
Atossa Genetics (ATOS) Analyst Forecast & Price Prediction
Start investing in Atossa Genetics (ATOS)
Order type
Buy in
Order amount
Est. shares
0 shares